-
2022-501417-31-00
5
High-risk Resected Melanoma
-
2023-504989-37-00
5
Metastatic Squamous Non-small Cell Lung Cancer
-
2024-513445-37-00
5
previously untreated RT, irrespective of risk factors and disease stag
-
2025-522145-21-00
5
Metastatic hormone sensitive prostate cancer
-
2025-522580-15-00
4
Amyotrophic Lateral Sclerosis (ALS)
-
2025-523400-72-00
4
Cystic fibrosis
-
2025-523558-14-00
1
Alpha-1 Antitrypsin Deficiency
-
2025-523576-23-00
5
Unresectable Stage III non-small cell lung cancer without progression
-
2025-523793-16-00
4
Homeostatic iron regulator gene-related hereditary hemochromatosis
-
2025-524002-16-00
5
2026-05-12
Amyotrophic Lateral Sclerosis
-
2025-522767-15-00
5
2026-01-27
Acute Myeloid Leukemia
-
2024-519901-36-00
5
2025-12-17
Patients with resected stage II-IIIA non-small cell lung cancer (NSCLC
-
2024-518296-56-00
5
2025-09-29
Crohn’s Disease
-
2024-512733-32-00
5
2025-03-31
Acute Myeloid Leukemia (AML)
-
2024-512536-29-00
4
2025-02-28
Amyotrophic Lateral Sclerosis (ALS)
-
2023-507853-13-00
4
2025-02-25
Ulcerative Colitis
-
2024-513077-48-00
5
2024-12-19
O6-methylguanine methyltransferase (MGMT) unmethylated glioblastoma
-
2022-502825-17-00
4
2024-10-07
Melanoma
-
2023-505678-14-00
4
2024-08-19
Ulcerative Colitis
-
2022-501105-12-00
5
2024-07-15
Urothelial Carcinoma
-
2022-501606-35-01
11
2024-02-21
Platinum-sensitive epithelial ovarian, fallopian tube, or primary
peri
-
2022-501157-36-00
6
2024-02-07
Critically ill patients who are dependent on high level medical care i
-
2022-501220-14-00
4
2023-10-17
epithelial ovarian, primary peritoneal, or fallopian tube cancer
-
2022-501007-28-00
5
2023-04-18
Breast Neoplasms